The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-SAP drags down German shares, COVID-19 worries weigh on broader Europe

Mon, 26th Oct 2020 09:43

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* German DAX closes at lowest in almost 4 months

* SAP cutting its 2020 outlook, posts worst fall in 24 years

* SAP's pessimism dents hopes of global recovery - analyst

* Oil drop pressures energy stocks
(Updates to close)

By Sruthi Shankar and Susan Mathew

Oct 26 (Reuters) - German shares closed at their lowest in
nearly four months on Monday as Europe's most valuable tech
firm, SAP, experienced its worst trading day in 24
years after cutting its 2020 outlook.

The German DAX fell 3.7% as SAP slumped
almost 22% after abandoning medium-term profitability targets
and cautioning that its business would take longer than expected
to recover from the pandemic hit.

"SAP's pessimism does not bode well for hopes for the global
economic recovery to continue," said Edward Moya, senior market
analyst at OANDA, New York.

"If tech goes, the deteriorating outlook due to virus spread
will likely yield massive risk aversion as investors head for
the sidelines instead of rotating into cyclicals."

The wider European tech index slid 7.4%.

SAP's results came as a blip in the third-quarter earnings
season, which has been largely better than feared.

Meanwhile, fresh COVID-19-induced restrictions in Italy and
Spain to curb a resurgence in cases weighed on the rest of
Europe, with the pan-European STOXX 600 index closing
at a one-month low, down 1.8%.

Europe on Saturday became the second region after Latin
America to surpass 250,000 deaths, according to a Reuters tally.

The euro zone blue-chip index fell nearly 3%,
while Europe's travel and leisure sector, worst hit by the
movement curbs, was down 3.3%.

Nick Nelson, head of European equity strategy at UBS, said
the Swiss bank's target for STOXX 600 into the year-end is 340
points, about 4.5% below the current level, in part due to the
impact of the latest round of restrictions.

Surveys of euro zone purchasing managers last week showed
economic activity slipped back into decline in October,
heightening expectations for a double-dip recession as a second
wave of virus sweeps across the continent.

Globally, risk appetite was sapped by worries over slow
progress on a new U.S. stimulus bill and a looming presidential
election.

Milan's blue-chip index fell 1.8% even as ratings
agency Standard and Poor's upgraded Italy's sovereign outlook to
stable from negative.

Oil majors Total and Royal Dutch Shell
fell over 2.8% as crude prices slumped more than 3% on demand
worries.

Healthcare stocks remained supportive, with
AstraZeneca gaining 1.7% after it resumed the U.S. trial
of its experimental COVID-19 vaccine.

French stocks dipped 1.9%. Turkish leader Tayyip
Erdogan asked his compatriots to stop buying French goods on
Monday in the latest expression of anger in the Muslim world
over images being displayed in France of the Prophet Mohammad,
which some Muslims consider blasphemous.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj
Kalluvila and Emelia Sithole-Matarise)

More News
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.